The US market for Biogen’s Tecfidera (dimethyl fumarate) blockbuster is to be commoditized, with four or five additional generic sponsors now seeking final approval and launch following a Delaware district court decision that has paved the way for further competition, a US healthcare investor has claimed.
A federal district court in Delaware has just decided that it was bound by an invalidity ruling obtained by




